Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep131 | Bone & Osteoporosis | ECE2016

Barrett’s esophagus and osteopenia: Report of a case

Athanassiou Panagiotis , Tzanavari Aikaterini , Spyridis Anestis , Kostopoulos Markos , Xanthakou Eleni , Kostoglou-Athanassiou Ifigenia

Introduction: Barrett’s esophagus is metaplasia in the cells of the lower end of the esophagus. It is characterized by the replacement of the normal stratified squamous epithelium lining of the esophagus by simple columnar epithelium with goblet cells. The disease is often related to gastroesophageal reflux and patients have pain necessitating chronic usage of proton pump inhibitors. Proton pump inhibitors have been associated with the development of low bone mineral dens...

ea0090p750 | Thyroid | ECE2023

Treatment Response With VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor, in Thyroid Eye Disease (TED): Phase 1/2 Clinical Study

Katz Barrett , Turbin Roger , Cockerham Kimberly , Tang Rosa , Nijhawan Navdeep , Ugradar Shoaib , O'Shaughnessy Denis J. , Summerfelt Rochelle M. , She Angela , Douglas Raymond

Purpose: IGF-1R antagonism reduces TED-related inflammation and proptosis. VRDN-001, a subnanomolar affinity full antagonist antibody to IGF-1R, is being evaluated in a phase 1/2 RCT (NCT05176639) at 3-20 mg/kg. We present results from the first cohort (10 mg/kg) of TED patients.Methods: Adults with active moderate-to-severe TED with clinical activity score (CAS) ≥4 were randomized to 2 infusions 3 weeks apart of either 10 mg/kg VRDN-001 or placebo...

ea0092op-09-01 | Oral Session 9: Thyroid Eye Disease | ETA2023

VRDN-001, a full antagonist antibody to IGF-1 receptor: in vitro pharmacology and phase 1/2 results in patients with thyroid eye disease (TED)

Douglas Raymond , Ugradar Shoaib , Turbin Roger , Cockerham Kimberly , Tang Rosa , Nijhawan Navdeep , Kossler Andrea , Boisvert Chantal , Lee Wendy , Yen Michael , Kaufman David , Yoon Michael , Bedian Vahe , Katz Barrett

Objectives: Antagonism of the IGF-1 receptor (IGF-1R) has been shown to reduce TED-related inflammation and proptosis. VRDN-001, a high-affinity antagonist antibody to IGF-1R, has distinct pharmacological properties that may enable differentiated dosing and better efficacy than observed with other antibodies. We assessed VRDN-001 in vitro pharmacology compared with teprotumumab and clinical proof of concept in a phase 1/2 randomized controlled trial (NCT05176639)....

ea0085oc7.3 | Oral Communications 7 | BSPED2022

Hypogonadism and pubertal disorders in wolfram syndrome

Newell Laura , Cunningham Olivia , Williams Denise , Barrett Timothy , Dias Renuka

Background: Wolfram Syndrome (WS) is a rare autosomal recessive disorder characterised by early-onset diabetes and optic atrophy as well as a variable spectrum of other endocrine and neurological conditions. It is caused by mutations in the WFS1 gene. Previous reports have documented a variable prevalence of hypogonadism (6.3% of the international EURO-WABB registry, 34% of a German cohort); however the only UK cohort reported was of 10 males, 7 of whom had primary gonadal atr...

ea0081rc13.1 | Rapid Communications 13: Adrenal and Cardiovascular Endocrinology 2 | ECE2022

HPA axis modulation by a potent inhibitor indicates 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) is a main source of cortisol that can bind intracellular receptors

Katz David , Mortier Mark

Background: HSD-1 converts cortisone to cortisol in tissues in which cortisol excess is associated with morbidity including liver, adipose, bone, and brain. SPI-62 is a potent HSD-1 inhibitor in clinical development for treatment of Cushing’s syndrome and autonomous cortisol secretion, and as adjunctive therapy to prednisolone in polymyalgia rheumatica. In Phase 1 clinical trials SPI-62 was generally well tolerated and associated with maximal liver and brain HSD-1 inhibit...

ea0066s3.3 | Diabetes Track 1: Symposium 3 | BSPED2019

Newer treatments for type 2 diabetes in children

Barrett Timothy

It is over 17 years since the randomised controlled trial of metformin showed efficacy in childhood type 2 diabetes. Since that time, despite much investment in paediatric investigation plans, very few interventional clinical trials have reported. This presentation reviews the evidence for childhood type 2 diabetes being different to adult type 2 diabetes. Childhood type 2 diabetes is a more aggressive disease; children have lower insulin sensitivity than adults; and complicat...

ea0019s31 | Polycystic ovarian syndrome (PCOS): when does it start, why and what to do about it? | SFEBES2009

Evolution of obesity and insulin resistance: relevance to PCOS

Barrett Tim

Polycystic ovarian syndrome (PCOS) is one of the commonest endocrine disorders of young women, and the commonest cause of reduced fertility in this age group. There are fundamental metabolic disturbances integral to the syndrome that lead to significant cardiovascular risk, and these include obesity, insulin resistance, beta cell dysfunction, impaired glucose tolerance and type 2 diabetes, dyslipidemia, hypertension, obstructive sleep apnoea, a pro-coagulant state, and endothe...

ea0085dpd1.2 | Diabetes and COVID Symposium | BSPED2022

Paediatric diabetes and SARS-CoV-2 - a riddle wrapped in a mystery inside an enigma

Ponmani Caroline , Barrett Michael

Background: Paediatric emergency departments saw an unusual increased incidence and severity of DKA in children with new onset diabetes in the COVID pandemic. The DIMPLES study (Diabetes Mellitus in children and young people presenting to the Emergency Department during the SARS-CoV-2 pandemic) explored this using retrospective multicentre data from 49 EDs, providing a unique perspective of paediatric diabetes from the frontline.Methods: We compared the ...

ea0029s27.3 | Are endogenous testosterone levels predictors of cardiovascular events? | ICEECE2012

Endogenous androgens, diabetes, and cardiovascular disease in women: the Rancho Bernardo study

Barrett-Connor E.

For >50 years female cardioprotection was attributed to premenopausal endogenous estrogen levels. We describe here how cardioprotection is greatly reduced in the presence of diabetes and endogenous testosterone levels.Forty years ago we measured total and bioavailable testosterone (bioT), total and bioavailable estradiol, and SHBG in community-dwelling older men and women from the Rancho Bernardo Study, using organic solvent extraction and celite col...